Vaughan David Investments LLC IL lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 307,565 shares of the company’s stock after acquiring an additional 4,751 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Vaughan David Investments LLC IL’s holdings, making the stock its 26th biggest holding. Vaughan David Investments LLC IL’s holdings in Johnson & Johnson were worth $44,954,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Gilbert & Cook Inc. lifted its stake in Johnson & Johnson by 3.3% in the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after acquiring an additional 288 shares during the period. 9258 Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.1% in the 4th quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after purchasing an additional 443 shares during the period. Gryphon Financial Partners LLC boosted its stake in shares of Johnson & Johnson by 66.3% during the fourth quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after purchasing an additional 5,680 shares in the last quarter. Horan Securities Inc. increased its holdings in Johnson & Johnson by 5.9% during the fourth quarter. Horan Securities Inc. now owns 4,952 shares of the company’s stock valued at $776,000 after buying an additional 274 shares during the period. Finally, Summit Place Financial Advisors LLC raised its stake in Johnson & Johnson by 16.5% in the fourth quarter. Summit Place Financial Advisors LLC now owns 19,268 shares of the company’s stock worth $3,020,000 after buying an additional 2,729 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $164.82 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The business has a fifty day moving average of $158.79 and a 200 day moving average of $153.93. The firm has a market capitalization of $396.67 billion, a price-to-earnings ratio of 10.28, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.
Wall Street Analyst Weigh In
JNJ has been the topic of a number of analyst reports. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. TD Cowen lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.
Check Out Our Latest Research Report on Johnson & Johnson
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- The How and Why of Investing in Gold Stocks
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Energy and Oil Stocks Explained
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.